79 results
424B3
CRVO
CervoMed Inc
6 Jun 24
Prospectus supplement
6:03am
they are approved;
the Company could be sued and held liable for injury caused to individuals exposed to or taking its product candidates … in the 149 subjects with AD and DLB treated with neflamapimod (vs. eight who were administered placebo), involving hypokalemia, myeloma, head injury
8-K
EX-10.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
or not consecutive) during any period of twelve (12) consecutive months, as a result of injury, illness or any other physical or mental impairment.
1.11. “Good
8-K
EX-10.2
5ulsrfd3kl1fqodcn6f
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
z2iy73e
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.3
x3oq5h4r
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
x2nb q900
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm
8-K/A
EX-99.3
eekije9lh65myn
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.2
k6nd xdyntj
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
424B3
15kjd9ycu1pvky ur6jy
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
zsmbqakpgmsfwcqgzg1
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
ea2pjwdh 81
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-10.2
2542a hp2
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-10.2
g5hihs7g1
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
8-K
EX-10.1
54qsxkj8tn p1jcne
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
424B5
fpxtryaf265dm7tx
22 Jul 22
Prospectus supplement for primary offering
4:15pm